Drug Trial Radar · NCT05827796
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Dec 8, 2022
Primary completion
Oct 11, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- InxMed (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
Conditions
- Pancreatic Cancer
Interventions
IN10018Drug
IN10018 orally once daily at approximately the same time each day, to ensure a dosing interval of approximately 24 hours.
Albumin-Bound PaclitaxelDrug
Albumin-bound paclitaxel will be administered as per the schedule specified in the respective arm.
GemcitabineDrug
Gemcitabine will be administered as per the schedule specified in the respective arm.
KN046Drug
KN046 5 mg/kg on Day 1 of each 21-Day Cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Related Adverse Events (AEs)Time frame: 1 year
- To evaluate the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in subjects with advanced pancreatic cancer.Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital of Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.